Cucurbit­[7]­uril (CB[7]) macrocycles exhibit a broad range of host–guest binding affinity. Attaching pendant CB[7] and complementary guests on 8-arm PEG macromers affords supramolecular hydrogels with cross-link affinity spanning more than 5 orders of magnitude (1.5 × 107 to 5.4 × 1012 M–1) without changing network topology. Cross-link affinity translates directly to bulk dynamic properties; hydrogels with high-affinity cross-linking behave like covalent gels with limited ability to relax or self-heal. Cross-link affinity furthermore dictates the release rate of encapsulated macromolecules, as well as cell infiltration and material clearance in vivo. This work thus informs a role for affinity in dictating supramolecular hydrogel properties by quantifying and isolating this feature over an unprecedented range.

No abstract

Ensuring effective drug concentration specifically at sites of need, while limiting systemic side effects, remains a challenge in the discovery and use of new drug molecules. Carriers targeted through biological affinity (e.g., antibodies) afford a common means of drug localization, yet often deliver considerably less than 1% of an administered drug to a desired site in the body. We report on an alternative targeting paradigm using pendant guest motifs to direct molecules to sites distinguished by a hydrogel bearing a high density of a complementary cucurbituril supramolecular host. Host–guest affinity ( K eq ) of 10 12 M –1 serves to spatially localize ∼4% of a model small molecule within hours of its administration in mice. These high-affinity interactions furthermore ensure long-lasting retention of the model compound at the site of interest, and the site can be serially targeted upon repeated dosing. This supramolecular homing axis extends the localization of small molecule payloads beyond injectable hydrogels, enabling targeting of modified biomaterials. This approach also has promising therapeutic utility, improving efficacy of a guest-modified chemotherapeutic agent in a tumor model.

The most advanced CdSe-based binary semiconductor system does not work well for emission in the short wavelength spectral region from 420 to 500 nm, which is of special interest for the preparation of nanocrystal-based blue LEDs and white light generation. CdxZn1−xSe alloy nanocrystals are proven to be an attractive alternative as their emission color can be tuned from the UV spectral region (ZnSe) to the red region (CdSe) by changing the composition of the Zn/Cd ratio in the alloy. Herein we report a facile and ‘green’ alloying approach for the preparation of highly luminescent CdxZn1−xSe nanocrystals via cation exchange reaction of the pre-prepared ZnSe nanocrystals with Cd2+ at intermediate temperatures. Through this new synthetic strategy, high-quality alloy QDs with different desired emission wavelengths or colors (ranging from 370 to 600 nm) can be made reproducibly and precisely by varying the predetermined amounts of the reaction precursors.

In diabetic patients, treatment with insulin and pramlintide (an amylin analogue) is more effective than treatment with insulin only. But because mixtures of insulin and pramlintide are unstable and have to be injected separately, amylin analogues are only used by 1.5% of diabetics needing rapid-acting insulin. Here, we show that the supramolecular modification of insulin and pramlintide with cucurbit[7]uril-conjugated polyethylene glycol improves the pharmacokinetics of the dual-hormone therapy and enhances post-prandial glucagon suppression in diabetic pigs. The co-formulation is stable for over 100 hours at 37 ºC under continuous agitation, whereas commercial formulations of insulin analogues aggregate after 10 hours under similar conditions. In diabetic rats, the administration of the stabilized co-formulation increased the area-of-overlap ratio of the pharmacokinetic curves of pramlintide and insulin to 0.7 ± 0.1 from 0.4 ± 0.2 (mean ± s.d.) for the separate administration of the hormones. The co-administration of supramolecularly stabilized insulin and pramlintide better mimics the endogenous kinetics of co-secreted insulin and amylin, and holds promise as a dual-hormone replacement therapy.